When Shiley Inc. and its parent Pfizer pulled the Björk-Shiley Convexo-Concave (BSCC) heart valve from the world market in 1986, the device had been sold for seven years as a refinement of an already trusted prosthesis — and the refinement was the thing that killed people. Co-invented by American engineer Donald Shiley and the Swedish cardiac surgeon Viking Björk, the convexo-concave disc was a geometric tweak meant to improve blood flow over the company’s well-regarded flat-disc tilting valve. To make the new geometry work, the outlet strut that captured the swinging disc was changed and welded to the valve ring. That weld was the flaw. Under the relentless cyclic load of roughly 40 million heartbeats a year, the strut fractured at the weld, the disc escaped, and the valve failed catastrophically — often producing sudden death before the patient could reach an operating room.
The harm was not a rare anomaly tolerated by an unlucky few. Of the roughly 86,000 convexo-concave valves implanted worldwide, more than 600 are documented to have fractured, and in approximately two-thirds of those cases the patient died. The 60-degree version received U.S. Food and Drug Administration approval in 1979; a higher-flow 70-degree variant was sold abroad but never cleared in the United States, and it fractured at even higher rates. Because the failure mode was a fatigue crack that gave no reliable warning, surgeons and patients spent the late 1980s and 1990s trapped in an excruciating calculus: a working valve might snap tomorrow, but elective re-operation to remove it carried its own mortality.
What turned a metallurgical defect into a scandal was the factory. Sworn testimony and a 1984 engineer’s complaint described a Shiley plant in Irvine, California where valves rejected by inspectors were fished back out, reground to hide cracked welds, renumbered, and passed with falsified paperwork — welders were poorly trained, equipment was in “horrible” condition, and struts were forced onto flanges with pliers. The legend of an improved valve concealed a manufacturing line that could not reliably make the one weld on which a patient’s life depended. Litigation, not the FDA, ultimately fixed the price: the Bowling v. Pfizer class action settled in 1992 for roughly $215 million, with a further fund earmarked for future fracture claims, while implanted patients carried the device — and the fear — for the rest of their lives.
When Medtronic Inc. suspended distribution of the Sprint Fidelis defibrillator lead on 15 October 2007, the gap between what the device promised and what it delivered was already measured in patients shocked awake by a machine guarding a heart that never faltered — and in others whose hearts stopped while a fractured wire stood silent. The Fidelis (models 6930, 6931, 6948, 6949) had been marketed since September 2004 as a refinement of an unglamorous component: the insulated wire that carries the sensing and high-voltage shock between an implantable cardioverter-defibrillator and the heart muscle. Its selling proposition was caliber. At 6.6 French — roughly 2.2 millimeters — it was the thinnest defibrillation lead on the market, slimmer than Medtronic’s own proven Sprint Quattro and easier to thread into the right ventricle. Thinner was sold as better. Thinner was the defect.
The harm took two mirror-image forms. When a Fidelis conductor fractured — and the thin, integrated cables fractured at higher-than-baseline rates near the can and the anchor sleeve — the lead generated electrical noise the ICD misread as a lethal arrhythmia, and the device did what it was built to do: it delivered a 30-to-40-joule shock into a fully conscious patient, sometimes dozens of times in a night. The opposite failure was worse. A fractured conductor could also break the circuit, so that when the patient genuinely arrested, the defibrillator could not deliver the therapy that was its entire reason to exist. Medtronic’s own analysis projected roughly 2.3 percent of leads fracturing within 30 months; independent center series ran far higher, near 3.75 percent per year against 0.6 percent for comparison leads. At least 13 deaths were ultimately linked to the lead.
Medtronic halted sales and recalled all unimplanted Fidelis leads; the FDA designated it Class I, its most serious category, reserved for products that may cause serious injury or death. But the defining feature was what did not happen: the roughly 268,000 leads already inside patients’ chests were largely left there. A defibrillator lead becomes encased in scar and bonded to the heart wall within months, and extraction can tear the vena cava or ventricle and kill the patient on the table. The recall could not undo itself. Patients were handed a probabilistic dilemma — leave a wire with a known, accelerating failure rate, or accept the lethal risk of pulling it — and a management tail that fell heavily on Medicare. A 2010 settlement of roughly 8,100 lawsuits for $268 million closed the litigation; it did not close the chests.
When Telectronics Pacing Systems issued a voluntary worldwide recall of its Accufix atrial “J” pacemaker leads on November 3, 1994 — a recall the U.S. Food and Drug Administration classified as Class I, its most severe category, reserved for products with a reasonable probability of causing serious injury or death — the device had already been doing precisely that. The Accufix lead carried, just behind its J-shaped tip, a thin metal “retention wire” whose only job was to hold the curve that anchored the electrode in the right atrial appendage. That wire fractured from metal fatigue, and the broken end could protrude through the lead’s polyurethane insulation and lacerate the atrial wall, the great vessels, even the aorta. The feature engineered to keep the lead in place became the mechanism that perforated the heart.
The gap between the design intent and the delivered harm was unusually stark because the failure was not rare. Radiographic screening of recalled-population patients found definite retention-wire fracture in 22.4 percent of leads examined, with the incidence climbing toward 25.6 percent on re-evaluation; the multicenter study put the fracture risk at roughly 5.6 percent per year. Roughly 45,000 leads had been implanted worldwide — about 25,000 of them in U.S. patients — across models 330-801 and 329-701. By the time of recall, Telectronics had logged two deaths and two non-fatal injuries; the worldwide registry would eventually record 40 spontaneous injuries, including 19 pericardial tamponades and six deaths.
What made the Accufix case distinct from a simple defective-device story was the trap it set after withdrawal. The lead could not simply be swapped like a battery: it was screwed into beating cardiac tissue and scarred in by years of healing. Extraction was itself lethal — fatal complications occurred in 0.4 percent of intravascular extraction procedures, 16 deaths among 4,023 attempts. Patients and cardiologists faced a documented dilemma with death on both arms: leave a fracturing wire in the heart and accept an annual protrusion risk, or pull it and accept an extraction-mortality risk that, for many low-fracture-risk patients, exceeded the hazard of leaving it alone. Telectronics funded the Accufix Research Institute to run the registry and study that quantified that trade-off, then exited the pacing business; the U.S. litigation consolidated as MDL-1057 and resolved in a settlement establishing a $58 million medical-monitoring and claims fund.
When C.R. Bard stopped selling its Recovery inferior vena cava filter in 2005, it did not recall the device or warn the roughly 34,000 patients carrying one inside the largest vein in the body; it replaced the Recovery with a cosmetically modified successor, the G2, and the gap between the promise and the harm was by then already documented in Bard’s own files. The Recovery was marketed as the first retrievable IVC filter cleared in the United States — a spider-shaped nitinol cage meant to catch blood clots traveling toward the heart and lungs and then, unlike permanent filters, to be removed once the danger passed. A confidential study Bard commissioned in 2004 found the opposite of a safe device: the Recovery carried higher relative risk of death, filter fracture, and migration than every competing filter on the market.
The failure mechanism was mechanical and lethal. The Recovery’s thin struts fractured, and the broken fragments — sharp lengths of nitinol — embolized through the bloodstream into the right heart and the pulmonary arteries, or the whole filter migrated and perforated the vena cava wall. A December 2005 internal Bard document, later obtained by NBC News, recorded that the Recovery had an “11.5 times higher reporting rate for filter embolization deaths” than all other vena cava filters combined. Bard had recruited a veteran regulatory specialist, Kay Fuller, to shepherd the FDA clearance; Fuller refused to sign the application over safety concerns, and the application reached the FDA bearing what she says is a forged version of her signature.
Rather than recall the Recovery after the 2004 report urged urgent investigation, Bard withdrew it from sale in 2005 and sold the G2 — a device Bard’s own records show it knew was fracturing and migrating within four months of clearance. The death toll surfaced not through a regulator but through a year-long NBC News investigation broadcast in September 2015, which linked the Recovery to at least 27 deaths and more than 300 non-fatal injuries. Thousands of suits consolidated into a multidistrict litigation in Arizona, and the first bellwether — Sherr-Una Booker, whose G2 fractured and required open-heart surgery — produced a $3.6 million verdict in March 2018, including $2 million in punitive damages. The FDA never recalled the Recovery; the legend of the “retrievable” filter ended as a case study in replacing a known-defective implant instead of retrieving it.